GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » PB Ratio

Windtree Therapeutics (Windtree Therapeutics) PB Ratio : 0.49 (As of May. 06, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-06), Windtree Therapeutics's share price is $4.94. Windtree Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $10.18. Hence, Windtree Therapeutics's PB Ratio of today is 0.49.

The historical rank and industry rank for Windtree Therapeutics's PB Ratio or its related term are showing as below:

WINT' s PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 1.93   Max: 372.81
Current: 0.49

During the past 13 years, Windtree Therapeutics's highest PB Ratio was 372.81. The lowest was 0.01. And the median was 1.93.

WINT's PB Ratio is ranked better than
92.45% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs WINT: 0.49

During the past 12 months, Windtree Therapeutics's average Book Value Per Share Growth Rate was -95.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -86.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -69.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Windtree Therapeutics was -38.50% per year. The lowest was -86.00% per year. And the median was -58.40% per year.

Back to Basics: PB Ratio


Windtree Therapeutics PB Ratio Historical Data

The historical data trend for Windtree Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics PB Ratio Chart

Windtree Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 1.25 1.08 0.66 1.27

Windtree Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.65 0.55 0.65 1.27

Competitive Comparison of Windtree Therapeutics's PB Ratio

For the Biotechnology subindustry, Windtree Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windtree Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's PB Ratio falls into.



Windtree Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Windtree Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=4.94/10.179
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Windtree Therapeutics  (NAS:WINT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Windtree Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Windtree Therapeutics (Windtree Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
Executives
Craig Fraser director, officer: Chief Executive Officer AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew officer: VP, Controller, & CAO WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck director 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill officer: SVP & CFO 4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc. 10 percent owner 7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc. 10 percent owner 7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman officer: SVP & General Counsel 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis officer: SVP & COO ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson officer: SVP, Chief Development Officer 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh director 75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott director
Joseph M Mahady director 16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber director 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976

Windtree Therapeutics (Windtree Therapeutics) Headlines

From GuruFocus